



## Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4<sup>th</sup> Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.

The live webcast of the presentation may be accessed via the Investors section of the Connect website at [investors.connectbiopharma.com](https://investors.connectbiopharma.com). An archived replay of the event will be available on the website for approximately 90 days following the conference.

### About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4R $\alpha$ . The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Sincere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately \$110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit [www.connectbiopharma.com](https://www.connectbiopharma.com).

### Investor Relations Contact:

Alex Lobo  
Precision AQ  
[Alex.lobos@precisionaq.com](mailto:Alex.lobos@precisionaq.com)  
(212) 698-8802

### Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull  
Russo Partners, LLC  
[ignacio.guerrero-ros@russopartnersllc.com](mailto:ignacio.guerrero-ros@russopartnersllc.com)  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)  
(858) 717-2310 or (646) 942-5604